Magdalena holds an MSc in Pharmaceutical Bioscience and an interdisciplinary PhD merging the fields of psychiatry, immunology and neuropharmacology. Her previous research focused on metabolic and immunologic changes in psychotic disorders. She is now focusing on science writing, allowing her to culture her passion for medical science and human health.
Evidence suggesting that bardoxolone methyl can delay kidney failure has surfaced in a re-analysis of data from a clinical trial in diabetics that was terminated over safety concerns, Reata Pharmaceuticals reports. ... Read more
Women with X-linked Alport syndrome may develop severe disease progression. But the type of mutation a patient carries does not predict the disease’s severity, and physicians should pay careful ... Read more
Billy Hudson, PhD, a researcher focusing on the Alport syndrome-associated collagen 4, has been awarded the 2018 Distinguished Investigator Prize by the International Society for Matrix Biology. The prize ... Read more
Regulus Therapeutics and Sanofi-Genzyme are among companies working on Alport syndrome therapies that can block RNA molecules’ actions. RG-012 is a man-made version of naturally occurring oligonucleotides, or RNA molecules that help regulate ... Read more
Australian researchers have identified a protein that is a possible biomarker of the progression of Alport syndrome and similar kidney diseases. They detected higher than normal levels of the ... Read more
The extent of loss of the COL4A5 protein in the kidneys of Alport syndrome patients is linked to a more severe disease progression, researchers at the Mayo Clinic in ... Read more